Effectiveness of Low-Dose Atropine (0.01% to 0.05%) in Reducing Myopia Progression: A Systematic Review and Meta-Analysis Authors: Abdullah S Alqahtani, Salma Hamdan Almarwani, Basmah Saeed Alweal, Mohammad Albadri, Lama Nasser Alghamdi, Bushra Wadi Bin Saddiq, Ahmed Salah Morad Published: 2026 ABSTRACT PurposeLow-dose atropine has been increasingly investigated as a pharmacological intervention to slow myopia progression in children. However, variability in atropine concentrations and reported outcomes across randomised clinical trials has led to uncertainty regrading its overall efficacy and safety. This systematic review and meta-analysis evaluated the efficacy and safety of low-dose atropine eye drops (0.01–0.05%) in slowing myopia progression in children.Patients and MethodsThis review followed PRISMA guidelines and was registered in PROSPERO (CRD42025635523). A comprehensive search of PubMed, ScienceDirect, MedLine, and the Cochrane Library was conducted in January 2025. Eligible studies were randomized controlled trials from 2019 to 2024 involving children aged 4–18 years with progressive myopia. Low-dose atropine concentrations evaluated across studies included 0.01%, 0.02%, 0.025%, and 0.05%, compared with placebo or control interventions. Data extraction and risk of bias assessment using the Cochrane Risk of Bias 2.0 tool were performed independently by multiple reviewers. Meta-analysis was conducted using Review Manager (RevMan) 5.4 on Mean changes in axial length and spherical equivalent. Fixed or random effects models were applied based on heterogeneity (I2).ResultsThirteen randomized controlled trials involving 2529 children were included. Low-dose atropine (0.01–0.05%) significantly reduced axial elongation compared with placebo (mean difference [MD]: −0.11 mm; 95% CI: −0.13 to −0.09; p < 0.00001) with substantial heterogeneity (I2 = 92%). Similarly, atropine was effective in slowing spherical equivalent progression (MD: +0.24 D; 95% CI: +0.14 to +0.33; p < 0.00001; I2 = 79%). Sensitivity analyses confirmed the robustness of these findings. Risk of bias was generally low across included trials, particularly for randomisation and incomplete outcome data, although some studies showed concerns related to participants blinding and outcome assessment. No substantial evidence of publication bias was observed.ConclusionLow-dose atropine (0.01–0.05%) may be an effective and generally safe intervention for slowing myopia progression in children. While the findings support its potential role in myopia control, further long-term trials are needed to clarify optimal dosing strategies and sustained post-treatment effects. Introduction Myopia is the most common refractive error worldwide and represents a growing public health concern, with a current global prevalence estimated at 33.9% and projections indicating that nearly 50% of the world’s population will be affected by 2050.1 The burden of myopia is particularly high in Saudi Arabia, where local studies report prevalence approaching 50%, exceeding rates observed in many Western countries.2 In response to this increasing prevalence, several interventions have been investigated to slow myopia progression, including increased time spent outdoors,3,4 optical strategies such as multifocal spectacles and contact lenses, and pharmacological approaches using topical antimuscarinic agents.5 Among these interventions, atropine eye drops have demonstrated consistent efficacy in reducing myopia progression across multiple randomized controlled trials.6–8 Although the precise mechanism of action of atropine remains incompletely understood, it is believed to involve M-cholinergic receptor antagonism with downstream effects on retinal signaling pathways and ocular growth, prompting investigation into whether its clinical efficacy is dose dependent.8 Evidence suggests that higher atropine concentrations provide greater myopia control but are also associated with increased adverse effects that may limit long term tolerability.9 Consequently, recent studies have shifted focus toward low-dose atropine regimens to balance efficacy and safety; however, findings regarding the comparative effectiveness and side effect profiles of low concentrations (0.01–0.05%) remain inconsistent across individual trials.6,7,10 Moreover, previous meta-analyses have evaluated a wide range of atropine doses or have not specifically focused on the low-dose spectrum most commonly used in current clinical practice.9 Therefore, this systematic review and meta-analysis aims to address this evidence gap by synthesizing available data on low-dose atropine (0.01–0.05%) to assess its effectiveness in reducing myopia progression measured by changes in axial length and refractive error while also evaluating associated adverse effects and tolerability, thereby providing clinically relevant evidence to guide optimal myopia management. Methodology Protocol and Registration This systematic review and meta-analysis were conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to ensure transparency and methodological rigor (Supplementary File 1). The protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO) under the ID CRD42025635523. Ethical approval was not required as the study involved only the secondary analysis of previously published data. Literature Search Strategy A comprehensive literature search was conducted in January 2025 across four electronic databases: PubMed, ScienceDirect, MedLine, and the Cochrane Library. No restrictions were placed on geographic region or publication date. The search strategy utilized both Medical Subject Headings (MeSH) and free-text terms, connected with Boolean operators. The terms used included: (Myopia OR Progressive Myopia) AND (Atropine) AND (Low-Dose Atropine OR 0.01% Atropine) AND (Axial Length OR Refractive Errors). The search strategy was guided by the PICOS framework (Population, Intervention, Comparison, Outcomes, and Setting) to identify relevant studies. Study Selection Eligible studies met the following inclusion criteria: randomized controlled trial (RCT) design, participants aged 4–18 years with progressive myopia, intervention with low-dose atropine (0.01–0.05%), and the use of a placebo, no treatment, or alternative myopia control method as a comparator. Studies were required to report outcomes related to myopia progression, including changes in axial length and spherical equivalent, as well as secondary outcomes such as side effects, tolerability, and quality of life. Studies were excluded if they were non-randomized, retrospective, case reports, or review articles; involved adults over 18 years or participants with other refractive errors; used high-dose atropine (>0.05%); or lacked a comparator group or relevant outcome measures. Screening and Data Extraction All articles retrieved during the database search were organized using a Google spreadsheet. Two independent reviewers (BB, AM) screened the titles and abstracts using Rayyan, a web-based tool for systematic reviews. Conflicts were resolved through discussion or by involving a third reviewer. Full texts of potentially eligible studies were then assessed against the inclusion criteria. Data extraction was conducted by one reviewer (SA) and verified by two others (BB, AM). Extracted variables included study characteristics, participant demographics, intervention details, and primary and secondary outcome measures. When data were presented only in graphical form, the GetData Graph Digitizer software was used to extract numerical values. In instances where mean changes from baseline were not directly reported, these values were calculated manually using the baseline and follow-up data provided in the studies. Missing standard deviations were estimated from confidence intervals or standard errors when necessary. All extracted data were double-checked to ensure accuracy and completeness. Assessment of Quality and Risk of Bias The methodological quality and risk of bias of each included RCT were independently evaluated by two reviewers (BB, BA) using the Cochrane Risk of Bias 2.0 (RoB 2) tool. This tool assesses five domains related to bias arising from the randomization process, deviations from intended interventions, missing outcome data, measurement of the outcome, and selection of the reported result. Each domain was judged as having a low risk of bias, some concerns, or a high risk of bias. These judgments were then used to determine the overall risk of bias for each study. Statistical Analysis and Meta-Analysis Meta-analysis was performed using Review Manager (RevMan) software, version 5.4. Statistical heterogeneity among studies was assessed using the Cochrane Q test and the I2 statistic. A random-effects model was used when significant heterogeneity was present (p < 0.05, I2 > 50%), while a fixed-effects model was applied in cases of low heterogeneity (p > 0.05, I2 < 50%). The primary outcomes were pooled using mean difference (MD) and reported with corresponding 95% confidence intervals (CIs). The analysis focused on the mean change from baseline in axial length and spherical equivalent refractive error. When mean changes were not reported, they were manually calculated by the authors based on baseline and endpoint values. A p-value of less than 0.05 was considered statistically significant. Results Search Result and Study Selection A total of 1089 articles were retrieved from four databases: PubMed (n = 300), ScienceDirect (n = 167), MedLine (n = 430), and Cochrane (n = 192). After removal of duplicates, 914 records were screened by title and abstract. Of these, 31 studies were assessed for full-text eligibility. Eighteen were excluded for not meeting inclusion criteria: 5 used high-dose atropine, 4 were not focused on children, 1 was not in English, and 8 had incompatible designs. Finally, 13 RCTs were included in the systematic review and meta-analysis (Figure 1).Figure 1PRISMA flow chart for screening and selection of included studies.A PRISMA flowchart for study selection in a systematic review.The flowchart illustrates the PRISMA process for identifying and selecting studies via databases and registers. Initially, records were identified from four sources: PubMed (300), Science Direct (167), MedLine (430) and Cochrane (192), totaling 1089 records. After removing 175 duplicate records, 914 records were screened. Of these, 883 were excluded, leaving 31 reports sought for retrieval. All 31 reports were retrieved and their eligibility was assessed. Eighteen reports were excluded for reasons such as not focusing on children (4), not available in English (1), using high-dose atropine instead of low-dose (5) and irrelevant study design (8). Finally, 13 studies were included in the review. PRISMA flow chart for screening and selection of included studies. Study Baseline Characteristics Thirteen RCTs comprising 2,497 children aged 4–16 years were included. The mean follow-up duration across studies was 13.6 months, ranging from 12 to 24 months. Gender distribution was generally balanced, with males comprising an average of 49.5% of the sample. The mean baseline axial length ranged from 22.21 mm to 24.85 mm, while the mean baseline spherical equivalent refractive error ranged from −1.19 D to −3.93 D across included trials. Additional characteristics including study design, sample sizes, and treatment durations are detailed in Tables 1 and 2. Table 1Summary of Included StudiesStudyYearSample Size (n)Age RangeGender %Follow-Up Duration (Months)interventionControlMaleFemaleWang et al, (2024)1120242001006-1250.749.312Audrey Chia et al (2023)12202373266-1147.552.512Liping Xia et al (2023)13202382826-16Group1: 537Group2: 524Group1: 46.3 Group2: 47.612Liang et al (2023)14202376836-12505012Jason C Yam et al (2019)620193271114-12505012Henry H L Chan et al (2022)15202234277-10NANA18Shweta Chaurasia et al (2022)16202240 right eye40 left eye6-16505012Simonaviciute et al (2024)17202455666-12356512James Loughman et al (2024)182024167836-1638.961.124Wei et al (2023)19202365686-12NANA24Weiqun Wang et al (2022)20202330306-1246.753.313Can Cui et al (2021)212021117: 001% 119: 002%1006-14524824Shifei Wei et al (2020)2220201101106-1246.853.212 Table 2Baseline CharacteristicsStudyBaseline Axial Length ChangeBaseline Spherical Equivalent Refractive ErrorAtropinePlaceboAtropinePlaceboMean (SD)TotalMean (SD)TotalMean (SD)TotalMean (SD)TotalWang et al, (2024)1124.58 (0.83)20024.42 (0.88)100−2.32 (1.29)200−2.27 (1.31)100Audrey Chia et al (2023)122477 (0.7)2524.79 (0.8)26−3.25 (1.1)25−3.93 (1.31)26Liping Xia et al (2023)132221 (1.48)8222.58 (1.62)82−2.76 (0.39)82−2.79 (0.42)82Liang et al (2023)142464 (0.78)7624.73 (0.97)83−2.69 (1.27)76−2.85 (1.45)83Jason C. Yam et al (2019)6247 (0.99)11024.82 (0.97)111−3.77 (1.85)110−3.85 (1.95)111Henry H. L. Chan et al (2022)152417 (0.79)3424.09 (0.74)27−1.88 (1.08)34−1.74 (0.71)27Shweta Chaurasia et al (2022)1624.52 (1.16)4324.56 (1.1)43−3.04 (1.36)43−3.07 (1.32)43Simonaviciute et al (2024)1724.46 (0.65)5524.16 (1.03)66−2.3855−2.0666James Loughman et al (2024)1824.85 (1.02)16724.93 (1.09)83−3.21167−3.3883Wei et al (2023)1924.62 (0.8)6524.72 (0.96)68−2.65 (1.29)65−2.74 (1.48)68Weiqun Wang et al (2022)2023.59 (0.77)3023.61 (0.75)30−1.19 (0.28)30−0.21 (0.32)30Can Cui et al (2021)2124.6 (0.72)10624.54 (0.69)89−2.76 for 0.01% −2.81 for 0.02% (1.56 for 0.01% 1.47 for 0.02%)106 for 0.01%105 for 0.02%−2.66 (1.39)89Shifei Wei et al (2020)2224.5 (0.76)11024.69 (0.97)110−2.52 (1.33)110−2.64 (1.46)110Abbreviation: SD, Standard deviation. Table 1Summary of Included StudiesStudyYearSample Size (n)Age RangeGender %Follow-Up Duration (Months)interventionControlMaleFemaleWang et al, (2024)1120242001006-1250.749.312Audrey Chia et al (2023)12202373266-1147.552.512Liping Xia et al (2023)13202382826-16Group1: 537Group2: 524Group1: 46.3 Group2: 47.612Liang et al (2023)14202376836-12505012Jason C Yam et al (2019)620193271114-12505012Henry H L Chan et al (2022)15202234277-10NANA18Shweta Chaurasia et al (2022)16202240 right eye40 left eye6-16505012Simonaviciute et al (2024)17202455666-12356512James Loughman et al (2024)182024167836-1638.961.124Wei et al (2023)19202365686-12NANA24Weiqun Wang et al (2022)20202330306-1246.753.313Can Cui et al (2021)212021117: 001% 119: 002%1006-14524824Shifei Wei et al (2020)2220201101106-1246.853.212 Summary of Included Studies Table 2Baseline CharacteristicsStudyBaseline Axial Length ChangeBaseline Spherical Equivalent Refractive ErrorAtropinePlaceboAtropinePlaceboMean (SD)TotalMean (SD)TotalMean (SD)TotalMean (SD)TotalWang et al, (2024)1124.58 (0.83)20024.42 (0.88)100−2.32 (1.29)200−2.27 (1.31)100Audrey Chia et al (2023)122477 (0.7)2524.79 (0.8)26−3.25 (1.1)25−3.93 (1.31)26Liping Xia et al (2023)132221 (1.48)8222.58 (1.62)82−2.76 (0.39)82−2.79 (0.42)82Liang et al (2023)142464 (0.78)7624.73 (0.97)83−2.69 (1.27)76−2.85 (1.45)83Jason C. Yam et al (2019)6247 (0.99)11024.82 (0.97)111−3.77 (1.85)110−3.85 (1.95)111Henry H. L. Chan et al (2022)152417 (0.79)3424.09 (0.74)27−1.88 (1.08)34−1.74 (0.71)27Shweta Chaurasia et al (2022)1624.52 (1.16)4324.56 (1.1)43−3.04 (1.36)43−3.07 (1.32)43Simonaviciute et al (2024)1724.46 (0.65)5524.16 (1.03)66−2.3855−2.0666James Loughman et al (2024)1824.85 (1.02)16724.93 (1.09)83−3.21167−3.3883Wei et al (2023)1924.62 (0.8)6524.72 (0.96)68−2.65 (1.29)65−2.74 (1.48)68Weiqun Wang et al (2022)2023.59 (0.77)3023.61 (0.75)30−1.19 (0.28)30−0.21 (0.32)30Can Cui et al (2021)2124.6 (0.72)10624.54 (0.69)89−2.76 for 0.01% −2.81 for 0.02% (1.56 for 0.01% 1.47 for 0.02%)106 for 0.01%105 for 0.02%−2.66 (1.39)89Shifei Wei et al (2020)2224.5 (0.76)11024.69 (0.97)110−2.52 (1.33)110−2.64 (1.46)110Abbreviation: SD, Standard deviation. Baseline Characteristics Abbreviation: SD, Standard deviation. Change in Axial Length A total of thirteen studies were included in the analysis of axial length change, encompassing 1,620 participants in the low-dose atropine group and 909 in the placebo group. As shown in Figure 2), this meta-analysis revealed a statistically significant reduction in axial elongation among those receiving low-dose atropine compared to placebo (Mean Difference = −0.11 mm, 95% CI [−0.13, −0.09], P < 0.00001). Heterogeneity across studies was substantial (I2 = 92%, χ2 = 143.65, P < 0.00001). The greatest reduction in axial length was observed in the study by Can Cui et al (MD = −0.56 mm, 95% CI [−0.65, −0.48]), whereas other studies, such as Henry H. L. Chan et al and Wei et al, demonstrated smaller or non-significant differences. Despite variability in effect sizes, the direction of effect was consistent, favoring low-dose atropine over placebo.18,19,20 Sensitivity analysis was conducted by excluding the study by Can Cui et al, which reported the largest treatment effect. This exclusion resulted in a slightly reduced overall mean difference (MD = −0.08 mm, 95% CI [−0.11, −0.06], P < 0.00001), with a substantial drop in heterogeneity (I2 = 25%, χ2 = 14.64, P = 0.20). This suggests that the findings are robust, and the originally observed heterogeneity was primarily attributable to the outlier effect of a single study.18,20 The high heterogeneity observed in the primary analysis likely reflects underlying clinical and methodological differences among trials, including variation in atropine concentration within the low-dose range (0.01–0.05%), baseline axial length and severity of myopia, duration of follow-up, and population characteristics. Although subgroup analyses stratified by dose, baseline refractive status, or follow-up duration would be clinically informative, such analyses were not feasible due to inconsistent reporting and limited availability of stratified data across the included studies.Figure 2Forest plot for change in axial length. Forest plot comparing the mean change in axial length between low-dose atropine and placebo groups. Each green square represents the mean difference for an individual study, and the size of the square reflects the study weight in the meta-analysis. Horizontal lines indicate 95% confidence intervals (CI). The vertical line at 0 represents no difference between groups. The diamond represents the pooled mean difference with its 95% CI. The overall pooled effect (fixed-effect model) showed a statistically significant reduction in axial length progression in the low-dose atropine group compared with placebo (mean difference −0.11 mm, 95% CI −0.13 to −0.09; Z = 11.91, P < 0.00001). Statistical heterogeneity was high (Chi2 = 143.65, df = 12, P < 0.00001; I2 = 92%).Forest plot comparing axial length change between low-dose atropine and placebo groups across studies.The table summarizes studies comparing low-dose atropine to placebo. Key columns include: Study, Low Dose Atropine (Mean, SD, Total), Placebo (Mean, SD, Total), Weight, Mean Difference IV, Fixed, 95% CI. Highlights: Audrey Chia et al reported a mean difference of -0.05; Can Cui et al found -0.56; Henry H. L. Chan et al observed 0.02; James Loughman et al noted -0.07; Jason C. Yam et al recorded -0.10; Liang et al showed -0.11; Liping Xia et al had -0.35; Shifei Wei et al reported -0.04; Shweta Chaurasia et al found -0.16; Simonaviciute et al observed -0.01; Wang et al noted -0.06; Wei et al recorded -0.06; Weiqun Wang et al showed -0.10. Total participants: 1620 in the atropine group and 909 in the placebo group, with an overall mean difference of -0.11 [-0.13, -0.09]. Forest plot for change in axial length. Forest plot comparing the mean change in axial length between low-dose atropine and placebo groups. Each green square represents the mean difference for an individual study, and the size of the square reflects the study weight in the meta-analysis. Horizontal lines indicate 95% confidence intervals (CI). The vertical line at 0 represents no difference between groups. The diamond represents the pooled mean difference with its 95% CI. The overall pooled effect (fixed-effect model) showed a statistically significant reduction in axial length progression in the low-dose atropine group compared with placebo (mean difference −0.11 mm, 95% CI −0.13 to −0.09; Z = 11.91, P < 0.00001). Statistical heterogeneity was high (Chi2 = 143.65, df = 12, P < 0.00001; I2 = 92%). Change in Spherical Equivalent Refraction (SER) Twelve of the thirteen included studies reported data on changes in spherical equivalent refraction, comprising a total of 1,370 participants in the low-dose atropine group and 827 in the placebo group. According to Figure 3, the pooled analysis showed a statistically significant improvement in SER among children treated with low-dose atropine, compared to those receiving placebo (Mean Difference = 0.24 D, 95% CI [0.14, 0.33], P < 0.00001). Moderate heterogeneity was observed (I2 = 79%, χ2 = 49.49, P < 0.00001). The most substantial treatment effect was seen in Shweta Chaurasia et al (MD = 0.46 D, 95% CI [0.35, 0.57]), while Henry H. L. Chan et al and Wei et al showed little or no difference between groups.19,20 The study by Simonaviciute et al did not provide data suitable for inclusion in the SER meta-analysis. A sensitivity analysis was conducted by excluding Henry H. L. Chan et al and Wei et al, both of which had near-null effects. The revised meta-analysis included 1,271 participants in the atropine group and 732 in the placebo group. The updated pooled estimate remained statistically significant (MD = +0.29 D, 95% CI [+0.21, +0.36], P < 0.00001), with a moderate decrease in heterogeneity (I2 = 66%, χ2 = 26.39, P = 0.002).20,23 These findings support the robustness of the observed SER effect in favor of low-dose atropine The observed heterogeneity is likely attributable to inter-study variability in atropine dosage, baseline refractive error, duration of treatment, and study population characteristics. Although subgroup analyses based on these factors were considered, inconsistent reporting and insufficient stratified data across trials precluded meaningful subgroup comparisons.23Figure 3Forest plot for change in SER. Forest plot comparing the mean change in spherical equivalent refraction (SER) between low-dose atropine and placebo groups. Each green square represents the mean difference for an individual study, with square size proportional to study weight. Horizontal lines indicate 95% confidence intervals (CI). The vertical line at 0 represents no difference between groups. The diamond represents the pooled mean difference with its 95% CI. The pooled analysis (random-effects model) demonstrated a statistically significant benefit favoring low-dose atropine (mean difference 0.24 D, 95% CI 0.14 to 0.33; Z = 5.03, P < 0.00001). Heterogeneity was substantial (Tau2 = 0.02; Chi2 = 49.49, df = 11, P < 0.00001; I2 = 79%). Superscript “a” indicates the Wald test statistic used to calculate the overall pooled effect.Forest plot comparing mean change in spherical equivalent refraction between low-dose atropine and placebo groups.The table summarizes studies comparing low-dose atropine and placebo effects. Columns include: Study, Low Dose Atropine Mean, SD, Total, Placebo Mean, SD, Total, Weight, Mean Difference IV, Random, 95% CI. Key findings: Audrey Chia et al showed a mean difference of 0.14 [-0.08, 0.36]; Can Cui et al had 0.47 [0.30, 0.63]; Henry H. L. Chan et al reported -0.04 [-0.24, 0.16]; James Loughman et al found 0.10 [-0.08, 0.28]; Jason C. Yam et al observed 0.37 [0.25, 0.49]; Liang et al noted 0.23 [0.08, 0.38]; Liping Xia et al had 0.36 [0.16, 0.56]; Shifei Wei et al showed 0.00 [-0.15, 0.15]; Shweta Chaurasia et al reported 0.46 [0.35, 0.57]; Wang et al found 0.11 [-0.06, 0.28]; Wei et al noted -0.01 [-0.15, 0.14]; Weiqun Wang et al observed 0.18 [0.06, 0.29]. Total (Walda): 1370, 827, 100%, 0.24 [0.14, 0.33]. Forest plot for change in SER. Forest plot comparing the mean change in spherical equivalent refraction (SER) between low-dose atropine and placebo groups. Each green square represents the mean difference for an individual study, with square size proportional to study weight. Horizontal lines indicate 95% confidence intervals (CI). The vertical line at 0 represents no difference between groups. The diamond represents the pooled mean difference with its 95% CI. The pooled analysis (random-effects model) demonstrated a statistically significant benefit favoring low-dose atropine (mean difference 0.24 D, 95% CI 0.14 to 0.33; Z = 5.03, P < 0.00001). Heterogeneity was substantial (Tau2 = 0.02; Chi2 = 49.49, df = 11, P < 0.00001; I2 = 79%). Superscript “a” indicates the Wald test statistic used to calculate the overall pooled effect. Risk of Bias Assessment The risk of bias of the included randomized controlled trials was independently evaluated using the Cochrane Risk of Bias 2 (RoB 2) tool, which assesses five predefined domains: bias arising from the randomization process, bias due to deviations from intended interventions, bias resulting from missing outcome data, bias in the measurement of outcomes, and bias in the selection of the reported result. Most trials were judged to be at low risk of bias with respect to randomization procedures, allocation concealment, and selective outcome reporting. Some concerns were noted in domains related to blinding of participants, study personnel, and outcome assessors, primarily due to insufficient or unclear reporting of masking methods. In addition, a limited number of studies demonstrated high or unclear risk of bias in the outcome measurement domain. Overall, the included trials were considered to have a low to moderate risk of bias, indicating acceptable methodological quality and supporting the internal validity of the pooled effect estimates. Detailed domain-level risk of bias judgments for each study are presented in Figures 4 and 5.Figure 4Risk of bias graph for included studies. Risk of bias assessment for each included study across predefined domains (random sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting, and other bias). Each row represents an individual study and each column represents a risk of bias domain. Green circles with a “+” indicate low risk of bias, yellow circles with a “?” indicate unclear risk of bias, and red circles with a “–” indicate high risk of bias.Risk of bias assessment for studies across various domains using color-coded indicators.The table has eight columns: Random sequence generation, Allocation concealment, Blinding of participants and personnel, Blinding of outcome assessment, Incomplete outcome data, Selective reporting, Other bias and Study names. Row summaries: 1. Audrey Chia et al - all positive. 2. Can Cui et al - unclear in allocation concealment, others positive. 3. Henry H. L. Chan et al - all positive. 4. James Loughman et al - all positive. 5. Jason C. Yam et al - all positive. 6. Liang et al - negative in allocation concealment, others positive. 7. Liping Xia et al - all positive. 8. Shifei Wei et al - negative in blinding of participants and personnel, others positive. 9. Shweta Chaurasia et al - unclear in blinding of participants and outcome assessment, others positive. 10. Simonaviciute et al - all positive. 11. Wang et al - all positive. 12. Wei et al - all positive. 13. Weiqun Wang et al - all positive.Figure 5Risk of Bias Summary.A stacked bar graph showing risk of bias judgments across bias domains in randomized controlled trials.A horizontal bar graph titled 'Risk of Bias Summary' shows bias percentages across seven domains: Random sequence generation, Allocation concealment, Blinding of participants and personnel, Blinding of outcome assessment, Incomplete outcome data, Selective reporting and Other bias. The x-axis ranges from 0% to 100%. Each domain's bar is divided into segments indicating Low, Unclear and High risk of bias. Legend: Low, Unclear, High risk of bias. Segment endpoints: Random sequence generation low to ~85%, unclear to 100%. Allocation concealment low to ~85%, unclear to ~92%, high to 100%. Blinding participants low to ~75%, unclear to 100%. Blinding assessment low to ~80%, unclear to 100%. Incomplete data low to ~85%, unclear to ~92%, high to 100%. Selective reporting low to 100%. Other bias low to ~85%, unclear to 100%. Risk of bias graph for included studies. Risk of bias assessment for each included study across predefined domains (random sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting, and other bias). Each row represents an individual study and each column represents a risk of bias domain. Green circles with a “+” indicate low risk of bias, yellow circles with a “?” indicate unclear risk of bias, and red circles with a “–” indicate high risk of bias. Risk of Bias Summary. Axial length and spherical equivalent both show symmetry, indicating a low risk of publication bias. Results are shown in the funnel plots in Figures 6 and 7.Figure 6Funnel plot for Axial Length. Funnel plot assessing potential publication bias for studies reporting axial length change. Each open circle represents an individual study plotted according to its mean difference (MD) and standard error (SE). The vertical dashed line represents the pooled effect estimate. The outer dashed diagonal lines indicate the pseudo 95% confidence limits around the pooled effect. Symmetry of the distribution suggests absence of significant publication bias.A scatter plot showing mean difference and standard error from negative 2 to 2 and 0 to 0.5.The funnel plot for Axial Length features MD on the horizontal axis, marked from -2 to 2 and SE(MD) on the vertical axis, ranging from 0 to 0.5. A vertical dashed line at MD=0 extends from SE(MD)=0 to 0.5. Two diagonal dashed lines create a funnel shape, converging near MD=0 and SE(MD)=0 and widening to MD=-1 at SE(MD)=0.5 on the left and MD=1 at SE(MD)=0.5 on the right. Study points, represented by open circles, cluster near MD=0 and SE(MD)=0, with some overlapping. One circle is outside the funnel at MD=-0.6, SE(MD)=0.05 and another inside on the left at MD=-0.4, SE(MD)=0.35.Figure 7Funnel plot for spherical equivalent refraction (SER). Funnel plot assessing potential publication bias for studies reporting spherical equivalent refraction (SER) change. Each open circle represents an individual study plotted according to its mean difference (MD) and standard error (SE). The vertical dashed line represents the pooled effect estimate. The outer dashed diagonal lines indicate the pseudo 95% confidence limits around the pooled effect. Symmetry of the distribution suggests absence of significant publication bias.A scatter plot showing mean difference from negative 2 to 2 and standard error from 0 to 0.2.A funnel scatter plot showing open-circle study points within two diagonal dashed boundary lines and a central vertical dashed line. The horizontal axis label is MD, with tick labels at negative 2, negative 1, 0, 1 and 2. The horizontal axis range shown is negative 2 to 2. The vertical axis label is SE(MD), with tick labels at 0, 0.05, 0.1, 0.15 and 0.2. The vertical axis range shown is 0 to 0.2, with 0 at the top and 0.2 at the bottom. A vertical dashed line is positioned slightly to the right of 0 on the MD axis. Two diagonal dashed lines form a funnel shape, meeting near the top of the plot and widening toward the bottom. Open-circle points are clustered around MD values near 0 to about 0.6 and SE(MD) values near 0.05 to about 0.12. Several points lie near SE(MD) about 0.05 at MD around 0.2 to 0.5. Additional points appear around SE(MD) about 0.08 to 0.12 at MD around 0 to 0.4. No points are shown near MD tick labels negative 2, negative 1, 1, or 2. Funnel plot for Axial Length. Funnel plot assessing potential publication bias for studies reporting axial length change. Each open circle represents an individual study plotted according to its mean difference (MD) and standard error (SE). The vertical dashed line represents the pooled effect estimate. The outer dashed diagonal lines indicate the pseudo 95% confidence limits around the pooled effect. Symmetry of the distribution suggests absence of significant publication bias. Funnel plot for spherical equivalent refraction (SER). Funnel plot assessing potential publication bias for studies reporting spherical equivalent refraction (SER) change. Each open circle represents an individual study plotted according to its mean difference (MD) and standard error (SE). The vertical dashed line represents the pooled effect estimate. The outer dashed diagonal lines indicate the pseudo 95% confidence limits around the pooled effect. Symmetry of the distribution suggests absence of significant publication bias. Discussion This meta-analysis reinforces the effectiveness of low-dose atropine (0.01%—0.05%) in managing myopia progression in children as evidenced by axial length (AL) increase and spherical equivalent refraction (SER) changes. Our findings are consistent with other meta-analyses23,24 but also expand their scope by showing that low-dose atropine does substantially decrease axial elongation compared to control (MD: −0.11 mm; 95% CI: −0.13 to −0.09) and SER progression (MD: +0.24 D; 95% CI: +0.14 to +0.33). Reduction in axial elongation is especially important because it correlates anatomically with myopia progression. Moreover, it directly strengthens the link with incidence of sight threatening complications like myopic maculopathy and retinal detachment in adulthood.25,26 Their impact on axial length has clinical significance, meaning even minimal concentration of atropine may alter the eye’s elongation dynamics during key developmental periods. Moderate to high levels of heterogeneity were seen in both the AL and SER analyses (I2 = 92%, 79% respectively). However, sensitivity analyses (for example, exclusion of Can Cui et al and Henry H. L. Chan et al studies) proved the robustness of such results, increasing treatment effect consistency and significantly decreasing heterogeneity.18,19 This implies that variability may stem from methodological differences or outliers rather than fundamental inconsistency in atropine’s efficacy.19 It is noteworthy that studies using slightly higher concentrations within the low-dose range (eg., 0.05%) reported relatively greater treatment effects, which supports the dose-dependent response seen in other investigations.6 However, higher doses may be associated with more side effects such as photophobia or near vision blur, which must be weighed against clinical benefits.27 Importantly, the risk of bias was generally low across the included randomized controlled trials, with most studies showing adequate randomization, blinding, and outcome reporting. However, a few studies presented unclear or high risks in allocation concealment and outcome assessor blinding, which should be considered when interpreting the pooled results. These findings are particularly relevant given the global rise in childhood myopia prevalence, especially in East Asia.1 Early intervention with safe and effective pharmacological agents like low-dose atropine can significantly alter the course of myopia progression, offering long-term visual and economic benefits.28 Despite the encouraging results, limitations should be acknowledged. Follow-up durations varied between studies, and long-term efficacy and safety data beyond 2–3 years are still limited. Additionally, racial and environmental factors—such as outdoor activity and near work—were inconsistently reported, though they are known to influence myopia development.4,29 Conclusion This systematic review and meta-analysis indicates that Low-dose atropine (0.01–0.05%) is associated with a statistically significant reduction in axial elongation and spherical equivalent progression in children with myopia compared with placebo. The findings suggest a potential beneficial role for low-dose atropine in myopia control; however, the observed heterogeneity across studies and methodological limitations in some trials warrant cautions interpretation. While low-dose atropine appears to be generally well tolerated, current evidence is insufficient to definitively establish its role as a universal first-line therapy. Further large scale, long term randomised controlled trials are needed to determine optimal dosing strategies, assess sustained efficacy after treatment cessation, and better characterise long term safety outcomes.